ALL Hub cover art

ALL Hub

ALL Hub

By: Scientific Education Support
Listen for free

This Season's Biggest Deal | $0.99/mo for 3 months + $20 Audible bonus

Auto-renews at $8.99/mo. after 3 months - terms apply.
Summary
The ALL Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in ALL. Our aim is to enhance knowledge in ALL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.

Scientific Education Support
Episodes
  • How should patients with ALL be selected for blinatumomab treatment?
    Oct 15 2026

    In this interview, Chiaretti discusses the key considerations when determining the number and duration of blinatumomab treatment cycles in B-ALL. She highlights factors that may inform treatment duration, including Philadelphia chromosome status, MRD response and genomic features. She also discusses clinical evidence supporting different treatment schedules across B-ALL treatment settings and the ongoing investigations into the optimal number and duration of blinatumomab cycles.


    Intended for healthcare professionals. This educational resource is independently supported by Amgen. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    4 mins
  • What is the potential impact of integrating reduced-chemo and chemo-free approaches into ALL treatment strategies? 
    Sep 29 2026

    The ALL Hub was pleased to speak with Elias Jabbour, MD Anderson Cancer Center, Houston, US. We asked, What is the potential impact of integrating reduced-chemotherapy and chemotherapy-free approaches into acute lymphoblastic leukemia (ALL) treatment strategies?


    In this interview, Jabbour discusses the growing evidence supporting chemotherapy-reduced and chemotherapy-free treatment approaches in ALL. He highlights how advances in targeted therapies, including blinatumomab, inotuzumab ozogamicin, tyrosine kinase inhibitors, and CAR T-cell therapy, together with measurable residual disease-guided treatment strategies, are transforming the management of ALL. Drawing on recent clinical studies, he explores the potential to reduce chemotherapy intensity, minimize the need for allogeneic stem cell transplantation, and improve long-term outcomes across different ALL subtypes and patient populations.


    This educational resource is independently supported by Amgen. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    5 mins
  • Obe-cel for relapsed/​refractory B-ALL: The FELIX study
    Aug 11 2026

    During the ALL Hub Steering Committee meeting in April 2026, Daniel DeAngelo led a discussion on the latest findings from the phase Ib/II FELIX trial (NCT04404660) investigating obecabtagene autoleucel (obe-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). The discussion featured contributions from Ibrahim Aldoss, José María Ribera, André Baruchel, Wendy Stock, and Nicolas Boissel.


    This educational resource is independently supported by Autolus. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    37 mins
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.